Hospitalizations among HIV controllers and persons with medically controlled HIV in the U.S. Military HIV Natural History Study

Trevor A Crowell§1,2, Anuradha Ganesan2,3,4, Stephen A Berry5, Robert G Deiss2,4,6, Brian K Agan2,4 and Jason F Okulicz§6,7 for the Infectious Disease Clinical Research Program (IDCRP) HIV Working Group

§Corresponding authors: Trevor A Crowell, U.S. Military HIV Research Program, 6720-A Rockledge Dr., Suite 400, Bethesda, MD 20817, USA. Tel: +1 301 500 3990, Fax: +1 301 500 3666. (tcrowell@hivresearch.org); Jason F Okulicz, Infectious Disease Service, San Antonio Military Medical Center, 3551 Roger Brooke Dr., Fort Sam Houston, San Antonio, TX 78234, USA. Tel: +1 210 916 3369. (jason.f.okulicz.mil@mail.mil)

This work was presented, in part, at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada, 19–22 July 2015.

Abstract

Introduction: HIV controllers (HICs) experience relatively low-level viraemia and CD4 preservation without antiretroviral therapy (ART), but also immune activation that may predispose to adverse clinical events such as cardiovascular disease and hospitalization. The objective of this study was to characterize the rates and reasons for hospitalization among HICs and persons with medically controlled HIV.

Methods: Subjects with consistently well-controlled HIV were identified in the U.S. Military HIV Natural History Study. ART prescription and HIV-1 RNA data were used to categorize subjects as HICs or medically controlled as defined by ≥ 3 HIV-1 RNA measurements ≤ 2000 or ≤ 400 copies/mL, respectively, representing the majority of measurements spanning ≥ 12 months. Hospitalizations were tallied and assigned diagnostic categories. All-cause hospitalization rates were compared between groups using negative binomial regression.

Results and discussion: Of 3106 subjects followed from 2000 to 2013, 221 were HICs, including 33 elite (1.1%) and 188 viraemic (6.0%) controllers, who contributed 882 person-years (PY) of observation time. An additional 870 subjects with medically controlled HIV contributed 4217 PY. Mean hospitalization rates were 9.4/100 PY among HICs and 8.8/100 PY among medically controlled subjects. Non-AIDS-defining infections were the most common reason for hospitalization (2.95/100 PY and 2.70/100 PY, respectively) and rates of cardiovascular hospitalization were similar in both groups (0.45/100 PY and 0.76/100 PY). There was no difference in hospitalization rate for HICs compared with subjects with medically controlled HIV (adjusted incidence rate ratio 1.15 [95% confidence interval 0.80 to 1.65]).

Conclusions: All-cause and cardiovascular hospitalization rates did not differ between HICs and persons with medically controlled HIV. Non-AIDS defining infections were common in this young, healthy, predominantly male cohort of military personnel and beneficiaries.

Keywords: HIV; HIV non-progressors; patient admission; hospitalization; highly active antiretroviral therapy.

Introduction

HIV controllers (HICs) include both viraemic and elite controllers who are characterized by the ability to spontaneously suppress plasma HIV RNA to low or undetectable levels, respectively, in the absence of antiretroviral therapy (ART) [1–4]. These individuals naturally experience relative CD4 preservation and delayed disease progression [3,4]. However, persistent low-level viral replication in the plasma and tissues may contribute to adverse clinical events. Even elite controllers may demonstrate viraemia that is detectable by ultrasensitive assays and can exceed that which is observed among persons with well-controlled HIV on ART [5–7].

HICs have elevated markers of microbial translocation, T-cell activation, coagulation cascade activation and systemic inflammation as compared to those observed among HIV-negative persons and HIV-positive persons who are well-controlled on ART [8–11]. Separately, each of these markers has been associated with increased risk for morbidity and mortality among persons living with HIV [12–15]. These factors may contribute to the observation that elite controllers who are not prescribed ART suffer from a high burden of subclinical cardiovascular disease [16,17]. Similarly, recent evidence suggests that elite controllers may have higher rates of all-cause and cardiovascular disease-related hospitalizations than do persons with medically controlled HIV [18]. Understanding the risks of adverse clinical outcomes among HICs, including hospitalization, may inform decisions to initiate ART in this population.

The purpose of this study was to characterize the rates and reasons for hospitalization among HICs and persons with medically controlled HIV in a cohort of HIV-infected U.S. military personnel and beneficiaries.
Methods

Study population

The U.S. Military HIV Natural History Study (NHS) is an ongoing cohort study that has enrolled over 5800 HIV-infected military personnel and beneficiaries over the age of 18 since it began in 1986. Demographic, laboratory and clinical data are systematically collected. Subjects are seen approximately every six months. CD4 count, HIV RNA and other laboratory parameters are assessed according to the local standard of care using routine clinical assays. Hospitalization data have routinely been collected since 2000. Subjects followed from 2000 to 2013 were eligible for inclusion in this analysis. All subjects provided written informed consent prior to enrolment in the NHS, which has been approved by institutional review boards (IRBs) at participating sites. The Uniformed Services University of the Health Sciences IRB approved this analysis.

HIV control status

HICs included both elite and viremic controllers, as defined by at least three HIV-1 RNA measurements below the limit of detection or ≤ 2000 copies/mL, respectively, over a period of at least 12 months without ART, with such measurements representing the majority of measurements during the time period, as previously described [3]. The HIC period ended for elite controllers if a majority of HIV-1 measurements were detectable or if any single HIV-1 RNA measurement was ≥1000 copies/mL. The HIC period ended for viremic controllers when the majority of HIV-1 RNA measurements were ≥2000 copies/mL. HIC periods also ended with initiation of ART. Medically controlled subjects were defined by at least three HIV-1 RNA measurements ≤400 copies/mL over a period of at least 12 months, representing the majority of measurements over that time and beginning within one year of initiating continuous ART. Medical control ended when a majority of HIV-1 RNA measurements over 12 months were >400 copies/mL or if ART was discontinued. Subjects could not contribute observation time to more than one group.

Covariates

Race/ethnicity and sex were categorized by self-report. Age and duration of HIV infection were assessed on July 1 of each calendar year. CD4 and HIV-1 RNA were updated annually with the first available measurement.

Outcomes

All-cause hospitalizations were tallied annually by admission date. Diagnoses were extracted at the time of data entry into the cohort database by trained study staff, using ICD-9 data and chart review to assign unique NHS diagnostic codes. The primary reason for each hospitalization was ascertained using the first-listed NHS diagnostic code. Each hospitalization was assigned to one of 17 diagnostic categories adapted from the “first-level” categories used in the Agency for Healthcare Research and Quality’s Clinical Classifications Software [19]. These include system-based categories such as “cardiovascular” and “pulmonary.” These categories were modified so that specific infections and malignancies were categorized as AIDS-defining illnesses according to Centers for Disease Control and Prevention criteria [20]. Non-AIDS-defining infections and malignancies were assigned their own categories and not included in organ system categories. If NHS diagnostic codes were missing or insufficient to categorize hospitalizations, then free-text diagnosis descriptions were reviewed by two investigators who were blinded to other subject characteristics. Each investigator assigned a diagnostic category and discordant categorizations were resolved by consensus. HIV, chronic hepatitis B, chronic hepatitis C and oral candidiasis were not considered primary reasons for hospitalization since, alone, they are insufficient to justify hospitalization. If these were listed first, then the next-listed diagnosis not referring to one of these was considered the reason for hospitalization.

Data analysis

All-cause hospitalization rates were calculated by dividing the total number of hospitalizations by the aggregate person-time during each calendar year and were reported as hospitalizations per 100 person-years (PY). Univariable and multivariable negative binomial regression models were used to estimate incidence rate ratios (IRR) for hospitalization rates associated with pre-defined variables of interest including age, race/ethnicity, gender, first annual CD4 count and duration of HIV infection. The multivariable model also included indicators for calendar year to control for secular trends. Because hospitalizations were captured regardless of adherence to NHS study visits, years with missing CD4 data were still included in the analysis if data were available and criteria for HIV control were satisfied both before and after the missing year(s). Missing values were imputed by assuming a linear trend between known measurements up to four years apart.

All models used generalized estimating equations, clustered on subject, with exchangeable working correlation, robust variance estimators and an offset for person-time. A two-sided type I error of 5% was considered statistically significant. Analyses were performed using Stata 13.1 (StataCorp LP, College Station, TX, USA).

Results and discussion

From 2000 to 2013, 3106 subjects contributed to the NHS database and 1091 met inclusion criteria. The HIC group consisted of 221 subjects, including 33 elite controllers (prevalence 1.1%) and 188 viremic controller-indicator (6.0%), who contributed 882 PY of observation time. The medical control group included 870 subjects who contributed 4217 PY. The median age at the start of virologic control for the HIC and medical control groups was 32.2 and 33.8 years, respectively (p=0.025). Compared to subjects with medically controlled HIV, HICs tended to be younger at the time of HIV diagnosis (median 27.6 vs. 29.1 years, p<0.001), were more likely to self-identify as Black (54.3% vs. 40.1%, p<0.001) and female (10.9% vs. 5.3%, p=0.003) and had higher CD4 counts at diagnosis (median 632 vs. 422 cells/mm³, p<0.001) with lower HIV-1 RNA (median 1604 vs. 31,189 copies/mL, p<0.001) (Table 1).

A total of 455 hospitalizations were observed during 5098 PY of follow-up, including 83 among HICs and 372 among persons with medically controlled HIV. Mean hospitalization rates were 9.4/100 PY among HICs and 8.8/100 PY among medically controlled subjects. Within the HIC group, there was...
a trend toward fewer hospitalizations among elite controllers as compared to vireaemic controllers (4.6/100 PY vs. 10.4/100 PY, respectively, \( p/C30 \) 0.053). Only seven hospitalizations were observed among the 33 elite controllers in this study. NHS diagnostic codes were used to assign diagnostic categories to 179 hospitalizations, and the remaining 276 hospitalizations were categorized by investigator review.

Non-AIDS-defining infection was the most common reason for hospitalization among both HICs and persons with medically controlled HIV, representing 31% of all hospitalizations. Hospitalization for non-AIDS-defining infection occurred at a rate of 2.95/100 PY among HICs and 2.70/100 PY among subjects with medically controlled HIV (Table 2). Within the 140 hospitalizations in this category, the two most common diagnoses were respiratory infections including pneumonia and influenza (37 hospitalizations) and soft tissue infections including cellulitis and abscesses (21 hospitalizations). AIDS-defining illnesses were uncommon, with only a single case of non-Hodgkin lymphoma in a medically controlled subject.

Unadjusted and adjusted factors associated with all-cause hospitalization are presented in Table 3. Independent risk factors for hospitalization included age \( \geq 60 \) (IRR 2.16 [1.01 to 4.63], as compared with 18 to 29 years) and CD4 \( \leq 200 \text{ cells/mm}^3 \) (IRR 2.58 [1.46 to 4.57], as compared with \( > 750 \text{ cells/mm}^3 \)).

### Table 1. Demographic and clinical characteristics by HIV control status

| Characteristics                      | Spontaneous HIV controllers \( n = 221 \) (%) | Subjects with medically controlled HIV \( n = 870 \) (%) |
|--------------------------------------|---------------------------------------------|--------------------------------------------------------|
| **Age at HIV diagnosis [years]**     |                                             |                                                        |
| Median (IQR)                         | 27.6 (23.1–34.1)                            | 29.1 (24.0–36.4)                                       |
| 18–29                                | 134 (60.6)                                  | 463 (53.2)                                             |
| 30–44                                | 82 (37.1)                                   | 339 (39.0)                                             |
| 45–59                                | 4 (1.8)                                     | 60 (6.9)                                               |
| \( \geq 60 \)                        | 1 (0.5)                                     | 8 (0.9)                                                |
| **Race/ethnicity**                   |                                             |                                                        |
| White                                | 75 (33.9)                                   | 347 (39.9)                                             |
| Black                                | 120 (54.3)                                  | 349 (40.1)                                             |
| Hispanic                             | 15 (6.8)                                    | 111 (12.8)                                             |
| Other/unknown                        | 11 (5.0)                                    | 63 (7.2)                                               |
| **Gender**                           |                                             |                                                        |
| Male                                 | 197 (89.1)                                  | 824 (94.7)                                             |
| Female                               | 24 (10.9)                                   | 46 (5.3)                                               |
| **CD4 count at HIV diagnosis [cells/mm\(^3\)]** |                                     |                                                        |
| Median (IQR)                         | 632 (505–785)                               | 422 (299–570)                                          |
| \( > 750 \)                          | 65 (29.4)                                   | 78 (9.0)                                               |
| 501 to 750                           | 103 (46.6)                                  | 237 (27.2)                                             |
| 351 to 500                           | 40 (18.1)                                   | 254 (29.2)                                             |
| 201 to 350                           | 12 (5.4)                                    | 212 (24.4)                                             |
| \( \leq 200 \)                       | 1 (0.5)                                     | 89 (10.2)                                              |
| **HIV-1 RNA at HIV diagnosis [copies/mL]** |                                     |                                                        |
| Median (IQR)                         | 1604 (400–5562)                             | 31,189 (8500–91,599)                                   |
| \( \leq 400 \)                       | 70 (31.7)                                   | 37 (4.3)                                               |
| 401 to 2000                          | 51 (23.1)                                   | 48 (5.5)                                               |
| \( > 2000 \)                         | 100 (45.2)                                  | 785 (90.2)                                             |
| **Duration of HIV infection at study entry [years]** |
| \( < 1 \)                           | 84 (38.0)                                   | 208 (23.9)                                             |
| 1 to 3                               | 59 (26.7)                                   | 429 (49.3)                                             |
| 3 to 6                               | 30 (13.6)                                   | 159 (18.3)                                             |
| 6 to 10                              | 32 (14.5)                                   | 36 (4.1)                                               |
| 10 to 15                             | 13 (5.9)                                    | 31 (3.6)                                               |
| \( > 15 \)                           | 3 (1.4)                                     | 7 (0.8)                                                |

IQR, interquartile range.

\*Age was assessed on July 1 of the year of HIV diagnosis; \*CD4 and HIV-1 RNA measurements are the first available after HIV diagnosis; \*duration of HIV infection was assessed on July 1 of the year of entry into the study, which occurred when viral load criteria for medical or spontaneous control of HIV infection were satisfied.
There was no significant difference in hospitalization rate for HICs as compared to those with medically controlled HIV (IRR 1.15 [0.80 to 1.65]) after adjusting for age, race, sex, CD4, year and duration of HIV infection.

This analysis reveals no difference in hospitalization rates between subjects with spontaneous virologic control of HIV and those with HIV that is well controlled using ART. Non-AIDS defining infections were the most common reason for hospitalization in both groups examined in this study. Targeted interventions should be pursued, such as vaccines against influenza and pneumococcal pneumonia, and subjects with medically controlled HIV. Furthermore, the difference in hospitalization rates between elite controllers studied. This study was not adequately powered to detect a difference in hospitalization rates between elite controllers and subjects with medically controlled HIV. Furthermore, the military cohort evaluated here may have been too young to detect a difference in hospitalization rates driven by age-related diagnoses such as cardiovascular disease.

Non-AIDS-defining infections were the most common reason for hospitalization in both groups. Overall, hospitalization was statistically significant (p < 0.05). The multivariable model also included an indicator variable for calendar year to control for secular trends. Results in bold are considered statistically significant (p < 0.05).

*Age was assessed on July 1 of each calendar year; *CD4 measurements used in this analysis were the first available measurements for each calendar year; *duration of HIV infection was assessed on July 1 of each calendar year.

Table 2. Hospitalization rates by diagnostic category

| Diagnostic category          | Hospitalizations per 100 person-years |
|------------------------------|---------------------------------------|
|                              | Spontaneous HIV controllers | Subjects with medically controlled HIV |
| All-cause                    | 9.41                      | 8.82                             |
| Non-AIDS infection           | 2.95                      | 2.70                             |
| Cardiovascular               | 0.45                      | 0.76                             |
| Gastrointestinal/liver       | 0.79                      | 0.76                             |
| Psychiatric                  | 0.45                      | 0.90                             |
| Endocrine                    | 0                        | 0.09                             |
| Injury/poisoning             | 0                        | 0.47                             |
| Renal                        | 0.91                      | 0.19                             |
| Pulmonary                    | 0.34                      | 0.07                             |
| Non-AIDS cancer              | 0.11                      | 0.47                             |
| Orthopaedic                  | 0.79                      | 1.00                             |
| Neurologic                   | 0.23                      | 0.14                             |
| Symptom-based                | 0.79                      | 0.45                             |
| Haematologic                 | 0.45                      | 0.97                             |
| AIDS-defining illness        | 0                        | 0.02                             |
| Obsteric/gynaecologic        | 0.23                      | 0.19                             |
| Unclassified                 | 1.02                      | 0.31                             |
| Dermatologic                 | 0.23                      | 0.07                             |

Table 3. Factors associated with all-cause hospitalization

| Characteristic                  | Unadjusted IRR (95% CI) | Adjusted IRR (95% CI) |
|--------------------------------|-------------------------|-----------------------|
| HIV control status             |                         |                       |
| Medical control                | 1.0 (Ref)               | 1.0 (Ref)             |
| Spontaneous HIV control        | 1.07 (0.75 to 1.52)     | 1.15 (0.80 to 1.65)   |
| Age [years]a                   |                         |                       |
| 18 to 29                       | 1.0 (Ref)               | 1.0 (Ref)             |
| 30 to 44                       | 0.93 (0.67 to 1.30)     | 0.84 (0.57 to 1.18)   |
| 45 to 59                       | 1.48 (0.95 to 2.31)     | 1.14 (0.76 to 1.71)   |
| ≥ 60                           | 3.14 (1.58 to 6.24)     | 2.16 (1.01 to 4.63)   |
| Race/ethnicity                 |                         |                       |
| White                          | 1.0 (Ref)               | 1.0 (Ref)             |
| Black                          | 0.84 (0.59 to 1.22)     | 0.83 (0.60 to 1.14)   |
| Hispanic                       | 0.86 (0.55 to 1.35)     | 0.93 (0.60 to 1.45)   |
| Other/unknown                  | 0.80 (0.47 to 1.35)     | 0.90 (0.54 to 1.52)   |
| Gender                         |                         |                       |
| Male                           | 1.0 (Ref)               | 1.0 (Ref)             |
| Female                         | 1.28 (0.83 to 1.98)     | 1.28 (0.84 to 1.95)   |
| CD4 count [cells/mm³]b         |                         |                       |
| > 750                          | 1.0 (Ref)               | 1.0 (Ref)             |
| 501 to 750                     | 1.02 (0.73 to 1.41)     | 1.11 (0.79 to 1.54)   |
| 351 to 500                     | 1.15 (0.75 to 1.76)     | 1.24 (0.80 to 1.95)   |
| 201 to 350                     | 1.00 (0.64 to 1.56)     | 1.14 (0.72 to 1.80)   |
| ≤ 200                          | 2.33 (1.27 to 4.28)     | 2.58 (1.46 to 4.57)   |
| Duration of HIV infection [years]c |                       |                       |
| < 1                            | 1.0 (Ref)               | 1.0 (Ref)             |
| 1 to 3                         | 1.34 (0.70 to 2.54)     | 0.77 (0.41 to 1.44)   |
| 3 to 6                         | 1.23 (0.64 to 2.36)     | 0.65 (0.34 to 1.22)   |
| 6 to 10                        | 1.26 (0.66 to 2.40)     | 0.63 (0.33 to 1.19)   |
| 10 to 15                       | 1.62 (0.82 to 3.18)     | 0.72 (0.36 to 1.42)   |
| > 15                           | 3.50 (1.55 to 7.92)     | 1.43 (0.62 to 3.32)   |

IRR, incidence rate ratio; CI, confidence interval. Results in bold are statistically significant (p ≤ 0.05). The multivariable model also included an indicator variable for calendar year to control for secular trends. Results in bold are considered statistically significant (p ≤ 0.05).

*Age was assessed on July 1 of each calendar year; *CD4 measurements used in this analysis were the first available measurements for each calendar year; *duration of HIV infection was assessed on July 1 of each calendar year.
cardiovascular hospitalizations among HICs despite prior evidence of a high burden of cardiovascular disease in this population [16–18].

The overall hospitalization rates among HICs and persons with medically controlled HIV were low compared with other reports of hospitalizations among HIV-positive individuals. Recent reports have estimated all-cause hospitalization rates among persons living with HIV in the United States as 20.6 to 28.9 hospitalizations/100 PY [26–28]. These cohorts reported mean and median ages of about 45 years. By contrast, from 1999 to 2007, the overall hospitalization rate in the younger population of the NHS was only 13.7/100 PY [29]. Hospitalization rates observed in this study are lower than those observed in the general NHS population and are higher than the all-cause hospitalization rate among active duty U.S. military personnel, which was 5.5/100 PY in 2013 [30]. Low hospitalization rates in the military and NHS may make any difference in rates between HICs and subjects with medically controlled HIV more difficult to detect.

Differences between our findings and those reported in other cohorts may partially be explained by unique characteristics of the NHS, which predominantly includes young, healthy men with universal access to healthcare. The HICs in this analysis were roughly two decades younger than those in previous investigations, where mean and median ages ranged from 45 to 52 years [16–18]. This difference is especially important when considering the effects of age-related comorbidities, such as cardiovascular disease. Also, comorbidities are generally uncommon among subjects in the NHS, including those known to be associated with high hospitalization rates such as viral hepatitis [31–33].

Our study has several strengths. Universal access to healthcare reduces the possibility of selection bias based on access to care that is observed in other cohorts. This also minimizes the risk for incomplete capture of hospitalization data. Since military personnel are regularly screened for HIV, seroconversion data are available for most participants in the NHS, and we were able to control for duration of HIV infection in statistical models.

Our study is limited by the small sample size of HICs. Because of this, we were unable to perform statistical tests for comparisons of cause-specific hospitalizations and could not meaningfully compare hospitalizations between elite and vireamric controllers. Data on tobacco use were not available for inclusion in multivariable models and this factor could have influenced the results of this analysis. Certain variables known to be associated with hospitalization could not be included in multivariable models because they are too uncommon in the cohort. For example, the rate of injection drug use in the cohort is under 1%, partially due to the periodic random drug testing that occurs among military personnel [34]. The prevalence of chronic hepatitis B and/or C is only about 6% each [33]. The unique demographic characteristics of the NHS may limit generalizability of our findings to other populations of persons living with HIV.

Conclusions

Hospitalization rates did not differ between subjects with spontaneous virologic control of HIV and those with medically controlled HIV on ART. Non-AIDS defining infections were common and no difference in hospitalization rates related to cardiovascular disease was detected between HICs and persons with medically controlled HIV. The overall hospitalization rate in this young, healthy cohort of military personnel and beneficiaries was lower than that observed in other cohorts of persons living with HIV. Longer term follow-up of these subjects is needed, particularly to assess outcomes that are associated with aging, such as the development of cardiovascular disease.

Authors’ affiliations

1. U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; 2. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; 3. Infectious Disease Service, Walter Reed National Military Medical Center, Bethesda, MD, USA; 4. Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; 5. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 6. Infectious Disease Clinic, Naval Medical Center San Diego, San Diego, CA, USA; 7. Infectious Disease Service, San Antonio Military Medical Center, San Antonio, TX, USA

Competing interests

S.A.B. has served as a consultant for Bristol-Myers Squibb. The remaining authors have no competing interests to declare.

Authors’ contributions

TAC conceptualized and designed the study, conducted the initial analysis, interpreted the data and drafted the manuscript. AG collected clinical cohort data, contributed to the study design and analysis and revised and approved the final manuscript. SAB conceptualized the study, contributed to the study design and analysis and revised and approved the final manuscript. RGD and BKA collected clinical cohort data, contributed to the study design and analysis and revised and approved the final manuscript. JFO conceptualized and designed the study, collected clinical cohort data, interpreted the data and revised and approved the final manuscript.

Acknowledgements

Support for this work (IDCRP-000-05) was provided by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), under Inter-Agency Agreement Y1-IA-5072; a cooperative agreement between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the DoD (W81XWH-07-2-0067); a grant to S.A.B. from NIAID/NIH (K23AI084854).

Disclaimer

The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army, Navy, Air Force, Department of Defense, Uniformed Services University of the Health Sciences or the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

References

1. Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS. 2011;6(3):163–8.
2. Sajadi MM, Constantine NT, Mann DS, Charurat M, Dadaan E, Kadlecik P, et al. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr. 2009;50(4):403–8.
3. Okulicz JF, Marconi VC, Landrum MI, Wegner S, Weintrab A, Ganesan A, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis. 2009;200(11):1714–23.
4. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS. 2009;23(9):1163–9.
5. Lambotte O, Boufassa F, Mader Y, Nguyen A, Goujard C, Meyer L, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005;41(7):1053–6.

6. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2009;83(1):329–35.

7. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, Rothchild AC, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009;200(6):984–90.

8. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4+ T cell counts in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197(1):126–33.

9. Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One. 2011;6(1):e15924.

10. Krishnan S, Wilson EM, Sheikh V, Rupert A, Mendoza D, Yang J, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis. 2014;209(6):931–9.

11. Noel N, Boufassa F, Lecouroux C, Saez-Cirion A, Bourgeois C, Duryach-Remy C, et al. Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients. AIDS. 2014;28(4):467–76.

12. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of inflammatory and coagulation biomarkers and mortality in patients with HIV infection. J Infect Dis. 2012;206(10):1558–67.

13. Sandler NG, Ward NK, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90.

14. Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emu B, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS. 2011;25(17):2123–31.

15. Kuller LH, Tracy R, Belloso W, De Wit S, Lane HC, et al. Relationship between T cell activation and CD4 counts in HIV controller patients. AIDS. 2008;22(10):1558–67.

16. Hsue PY, Hunt PW, Schnell A, Kalapua SC, Hoh R, Ganz P, et al. Role of viral replication, antimicrobial therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23(9):1059–67.

17. Pereyra F, Lo J, Triant VA, Wei J, Buzon MJ, Fitch KV, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS. 2012;26(18):2409–12.

18. Crowell TA, Bebawy KA, Blankson JN, Korthuis PT, Yehia BR, Rustein RM, et al. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J Infect Dis. 2015;211(11):1692–702.

19. O’Connell RJ, Exner JL. HIV vaccine efficacy and immune correlates of risk. Curr HIV Res. 2013;11(6):450–63.

20. Castro KG, Ward JW, Stitik T, Buehler JW, Jaffe HW, Berkelman RL, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1–19.

21. Cortes FH, Passaes CP, Bello G, Teixeira SL, Vorsatz C, Babin D, et al. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles. J Acquir Immune Defic Syndr. 2015;68(4):377–85.

22. Ballana E, Ruiz-de Andres A, Mothe B, Ramirez de Arellano E, Aguilar F, Badia R, et al. Differential prevalence of the HLA-C*35 CC genotype among viremic long term non-progressor and elite controller HIV+ individuals. Immunobiology. 2012;217(9):889–99.

23. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197(4):563–71.

24. French N, Gordon SB, Mwulukwam T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362(9):812–22.

25. Beck CR, McKenzie BC, Hashim AB, Harris RC, Nguyen-Van-Tam JS. Influenza vaccination for immuno compromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206(8):1250–9.

26. Berry SA, Fleshman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite US cohort of persons living with HIV, 2001–2008. J Acquir Immune Defic Syndr. 2012;59(4):368–75.

27. Bachhuber MA, Southern WN. Hospitalization rates of people living with HIV in the United States, 2009. Public Health Rep. 2012;129(2):178–86.

28. Retnisch C, Tate JP, Algau KM, Crystal S, Wang KH, Ryan Greyson S, et al. Alcohol-related diagnoses and all-cause hospitalization among HIV-infected and uninfected patients: a longitudinal analysis of United States veterans from 1997 to 2011. AIDS Behav. 2015. doi: http://dx.doi.org/10.1007/s10461-015-1077-4.

29. Crowell TA, Berry SA, Fleshman JA, LaRue RW, Korthuis PT, Nijhawan A, et al. Impact of hepatitis coinfection on healthcare utilization among persons living with HIV. J Acquir Immune Defic Syndr. 2015;68(4):425–31.

30. Crowell TA, Gebo KA, Balagopal A, Fleshman JA, Agwu AL, Berry SA. Impact of hepatitis coinfection on hospitalization rates and causes in a multicenter cohort of persons living with HIV. J Acquir Immune Defic Syndr. 2014;65(4):429–37.

31. Brodine SK, Stanley MJ, Shaffer RA, No SI, Tasker SA, Barile AJ, et al. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003;17(17):2521–7.